Advertisement
BMRN vs VRTX
Which Stock Would AI Choose? BioMarin Pharmaceutical (BMRN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- BioMarin Pharmaceutical (BMRN) is a rare-disease specialist rebuilding momentum through dealmaking, including its Amicus acquisition and a new Fabry disease licensing pact.
- Vertex Pharmaceuticals (VRTX) combines a dominant, highly profitable cystic fibrosis (CF) franchise with a rapidly diversifying pipeline and strong recent share-price momentum.
- VRTX has delivered materially stronger relative performance and carries a far lower earnings multiple than BMRN, reflecting greater market confidence in its growth path.
- Tickeron AI Verdict: Based on trend consistency, stability, catalysts, and relative positioning, Tickeron's AI currently favors VRTX over BMRN.
- For more context on these names, explore BMRN Major News and BMRN Today's Price Move, as well as VRTX Major News and VRTX Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
Both BMRN and VRTX operate in the high-growth biotechnology sector, yet they occupy very different positions within it. BioMarin is a mid-cap developer of therapies for rare genetic diseases, while Vertex is a large-cap leader that has built one of the most valuable franchises in the industry around cystic fibrosis. This stock comparison is relevant for investors weighing a more established, cash-rich compounder against a smaller, deal-driven turnaround story. It is particularly useful for those tracking relative performance, market positioning, and near-term catalysts across the healthcare landscape.
BMRN Overview and Recent Performance
BMRN, or BioMarin Pharmaceutical Inc., develops and commercializes therapies for rare, life-threatening genetic conditions, with core products including Voxzogo (vosoritide) for achondroplasia and a metabolic conditions portfolio spanning Galafold, Palynziq, and others. In recent weeks, the company has leaned heavily on business development, completing its acquisition of Amicus Therapeutics and signing an exclusive worldwide license with GC Biopharma and Hanmi Pharm for an investigational long-acting enzyme replacement therapy targeting Fabry disease.
The stock has traded in a wide range during recent market activity, retreating from its 52-week high before stabilizing as investors digested competitive pressure on Voxzogo and the integration of newly acquired assets. BMRN carries a notably high price-to-earnings (P/E) ratio on trailing earnings, which reflects both modest near-term profitability and elevated expectations for future margin expansion. Analyst sentiment remains broadly constructive, with an average price target well above recent trading levels.
VRTX Overview and Recent Performance
VRTX, or Vertex Pharmaceuticals Incorporated, generates the overwhelming majority of its product revenue from its CF therapies, including Trikafta/Kaftrio and Alyftrek, while expanding into pain, kidney disease, hematology, and type 1 diabetes. Recent weeks have brought a steady flow of positive catalysts: Phase 3 RAINIER results for povetacicept in IgA nephropathy (a form of kidney disease) were published in the New England Journal of Medicine and presented at ASN Kidney Week, with an FDA decision date set for late November.
Vertex also announced its largest-ever acquisition, agreeing to buy Crinetics for roughly $10 billion to add a GLP-1 receptor agonist portfolio (drugs targeting metabolic and hormonal pathways). The stock has climbed to a fresh 52-week high, supported by these pipeline advances, and its trailing P/E ratio sits far below BMRN's, reflecting stronger current earnings and a more mature profitability profile.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's most compelling automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this focused section. These bots span a wide range of trading styles, timeframes, risk profiles, and performance statistics, with each strategy targeting its own specific set of tickers. Whether a trader is seeking short-term momentum signals or longer-horizon trend positioning, the page offers a practical way to compare approaches. Explore Trending AI Robots to see which automated strategies are currently standing out.
Head-to-Head Comparison
The sharpest contrast between these two names is scale and earnings quality. VRTX commands a market capitalization roughly twelve times that of BMRN and generates consistently positive, growing earnings, while BMRN's earnings remain comparatively thin and its multiple stretched. In terms of business model, BMRN relies on a broad but smaller rare-disease portfolio, whereas VRTX enjoys a near-monopoly in CF that produces substantial, predictable cash flow.
Growth drivers also diverge. BMRN's recent momentum is heavily tied to acquisitions and licensing deals, which carry execution and integration risk. VRTX, by contrast, is diversifying organically and through selective M&A (mergers and acquisitions), with a deep late-stage pipeline providing multiple potential product launches. Risk profiles differ accordingly: BMRN faces direct competitive threats to its flagship Voxzogo franchise and near-term deal-integration uncertainty, while VRTX's key risk is concentration in CF even as new pillars emerge. Market sentiment currently favors VRTX, which has outperformed on both a one-year and five-year basis and trades near record highs.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, earnings stability, momentum, and catalyst quality, Tickeron's AI would currently lean toward VRTX. Vertex combines a durable, highly profitable core business with a steady stream of near-term clinical and regulatory catalysts and stronger recent price momentum. BioMarin offers a potentially larger valuation re-rating opportunity but also carries higher competitive and execution risk. On balance, the AI's preference reflects VRTX's more favorable risk-reward profile and market positioning, though this is a probabilistic assessment rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and VRTX is a Buy.
BMRN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BMRN turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Indicator exited the oversold zone, 18 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on BMRN as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 162 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 65 cases where BMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
BMRN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.718) is normal, around the industry mean (2.904). BMRN's P/E Ratio (151.676) is considerably higher than the industry average of (-0.738). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for VRTX turns positive, indicating new upward trend
VRTX saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 60 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for VRTX just turned positive on October 20, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in 41 of 59 cases over the following month. The odds of a continued upward trend are 69%.
VRTX moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VRTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +5.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 236 of 369 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for VRTX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 25 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 63 cases where VRTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
VRTX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.791) is normal, around the industry mean (2.904). P/E Ratio (31.340) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (440.869).
BMRN | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 13 | |
SMR RATING 1..100 | 89 | 41 | |
PRICE GROWTH RATING 1..100 | 57 | 23 | |
P/E GROWTH RATING 1..100 | 1 | 39 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRTX's Valuation (90) in the Biotechnology industry is in the same range as BMRN (98). This means that VRTX’s stock grew similarly to BMRN’s over the last 12 months.
VRTX's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for BMRN (100). This means that VRTX’s stock grew significantly faster than BMRN’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for BMRN (89). This means that VRTX’s stock grew somewhat faster than BMRN’s over the last 12 months.
VRTX's Price Growth Rating (23) in the Biotechnology industry is somewhat better than the same rating for BMRN (57). This means that VRTX’s stock grew somewhat faster than BMRN’s over the last 12 months.
BMRN's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for VRTX (39). This means that BMRN’s stock grew somewhat faster than VRTX’s over the last 12 months.
| BMRN | VRTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 68% |
| Advances ODDS (%) | 7 days ago 58% | 7 days ago 64% |
| Declines ODDS (%) | 3 days ago 62% | 3 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 53% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRN’s FA Score shows that 1 FA rating(s) are green while VRTX’s FA Score has 2 green FA rating(s).
- BMRN’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRN’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).
- BMRN’s TA Score: 4 bullish, 4 bearish.
- VRTX’s TA Score: 5 bullish, 5 bearish.
Price Growth
BMRN (@Biotechnology) experienced а +2.02% price change this week, while VRTX (@Biotechnology) price change was +3.65% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.
Reported Earning Dates
BMRN is expected to report earnings on Feb 24, 2027.
VRTX is expected to report earnings on Feb 09, 2027.
Industries' Descriptions
@Biotechnology (-8.72% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement